Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Boehringer Testing Copy of Rituxan in Type of Lymphoma

Jan. 30 (Bloomberg) -- Boehringer Ingelheim GmbH started testing a version of Roche Holding AG’s top-selling drug Rituxan for non-Hodgkin’s lymphoma, broadening the possible uses the German company sees for its copy of the medicine.

Boehringer is already recruiting patients in another trial of the drug in rheumatoid arthritis and adding an indication in non-Hodgkin’s lymphoma, a type of cancer, may help increase sales, Asthika Goonewardene, a London-based analyst for Bloomberg Industries, said in a note to clients today.

“Boehringer’s efficient clinical program may generate the data required to file for regulatory approval in both the U.S. and EU for the two key indications which account for more than 90 percent of Rituxan sales,” Goonewardene wrote.

Boehringer is seeking to enter a crowded field of potential competitors. Novartis AG, Celltrion Inc., partners Samsung Electronics Co. and Quintiles Transnational Corp., and Teva Pharmaceutical Industries Ltd. with Lonza Group AG are among the companies already working on a Rituxan copy. Some of the companies have had setbacks in developing a Rituxan copy, Goonewardene wrote.

To contact the reporter on this story: Andrea Gerlin in London at agerlin@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.